IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Issue 3 (18th April 2013)

• Record Type: Journal Article
• Authors: Day, Elizabeth; Poulogiannis, George; McCaughan, Frank; Mulholland, Shani; Arends, Mark J.; Ibrahim, Ashraf E. K.; Dear, Paul H.
• Is Part Of: International journal of experimental pathology. Volume 94:Issue 3(2013:Jun.)
• Page Start: 203
• Page End: 211
• Publication Date: 2013-04-18
• Subjects: Pathology, Experimental -- Periodicals; 616.07
• DOI: 10.1111/iep.12021
• Languages: English
• ISSNs: 0959-9673

Abstract

<abstract abstract-type="main" xml:lang="en" id="iep12021-abs-0001"> <title>Summary</title> <p>Copy number alterations are frequently found in colorectal cancer (CRC), and recurrent gains or losses are likely to correspond to regions harbouring genes that promote or impede carcinogenesis respectively. Gain of chromosome 13q is common in CRC but, because the region of gain is frequently large, identification of the driver gene(s) has hitherto proved difficult. We used array comparative genomic hybridization to analyse 124 primary CRCs, demonstrating that 13q34 is a region of gain in 35% of CRCs, with focal gains in 4% and amplification in a further 1.6% of cases. To reduce the number of potential driver genes to consider, it was necessary to refine the boundaries of the narrowest copy number changes seen in this series and hence define the minimal copy region (MCR). This was performed using molecular copy‐number counting, identifying <italic>IRS2</italic> as the only complete gene, and therefore the likely driver oncogene, within the refined MCR. Analysis of available colorectal neoplasia data sets confirmed <italic>IRS2</italic> gene gain as a common event. Furthermore, IRS2 protein and mRNA expression in colorectal neoplasia was assessed and was positively correlated with progression from normal through adenoma to carcinoma. In functional <italic>in vitro</italic> experiments, we demonstrate that deregulated expression of IRS2 activates the oncogenic PI3 kinase pathway and increases cell adhesion, both characteristics of invasive CRC cells. Together, these data identify <italic>IRS2</italic> as a likely driver oncogene in the prevalent 13q34 region of gain/amplification and suggest that IRS2 over‐expression may provide an additional mechanism of PI3 kinase pathway activation in CRC.</p> </abstract>